LILY SMOLINSKI: Open Payments
NPI 1821511809 · HUMBLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$663 in 42 payments from 14 companies in 2025. Trend: 2023 $559 · 2024 $778 · 2025 $663
Food & beverage: $663
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $175 |
| Lilly USA, LLC | 5 | $91 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Exact Sciences Corporation | 3 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| ABBVIE INC. | 2 | $42 |
| Celltrion USA Inc. | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
Products named: Ozempic, MOUNJARO, TRELEGY ELLIPTA, JARDIANCE, Cologuard Collection Kit, Wegovy, REXULTI, VEGZELMA.
Industry payments across TX — which companies pay providers there.
